This site is intended for healthcare professionals
News

New Data for Genentech’s Hemlibra reinforce safety profile in people with hemophilia A.

Read time: 1 mins
Last updated:28th Jul 2021
Published:19th Jul 2021
Genentech, a member of the Roche Group announced results from the final analysis of the Phase IIIb STASEY study, which confirm the favorable safety profile of Hemlibra (emicizumab-kxwh), consistent with the Phase III HAVEN clinical program. In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with hemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with hemophilia A. The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, July 17-21.
Condition: Haemophilia A
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest